{"entity":{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","aka":[],"tldr":"When a health system pays for a new, uncertain cancer drug, it would require that every patient's outcome is recorded and that a pre-agreed analysis decides whether payment continues.","summary":"Coverage with evidence development exists (the English Cancer Drugs Fund, Medicare CED, Italy's AIFA registries) but analyses are often weak, late or never published. The proposal standardises the model: a pre-registered statistical analysis plan agreed at listing, mandatory structured data capture, an independent analysis body, a fixed decision date, and publication of results whatever the outcome.","asOf":"2026-09-08","links":[{"label":"NICE Cancer Drugs Fund","url":"https://www.england.nhs.uk/cancer/cdf/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-real-world-evidence","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Standardised CED with pre-specified analyses will produce a reimbursement decision for more than 90 percent of conditionally funded indications within three years, and will lead to withdrawal or price reduction in a meaningful share.","rationale":"The reformed Cancer Drugs Fund (2016) cleared its backlog by fixing decision dates and data collection; AIFA registries have supported outcome-based rebates. Standardising the analytic component is the missing piece.","test":"Audit all CED decisions in three systems over five years for timeliness and publication; introduce the standardised model in one and compare.","maturity":"being-tested-at-scale","actor":"payer","cost":"medium","horizonYears":3},"route":"/ideas/idea-data-coverage-with-evidence-development/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"term":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"idea":[{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","route":"/ideas/idea-data-outcome-based-price-reassessment/"}]}}